US FDA does not need to issue Written Confirmations by 2 July 2013
Recommendation

6/7 October 2026
In a Press Release the US FDA announced that the U.S. is now a "listed country" with the European Commission (EC) so that U.S. companies need not obtain an export certificate from the FDA before shipping certain pharmaceutical products to Europe.
Without the waiver, all U.S. companies shipping active pharmaceutical ingredients (APIs) to Europe after July 1, 2013 would have had to first submit documentation from the FDA that the product was manufactured in accordance with Europe's good manufacturing practices. The EC has now approved that request following a comprehensive audit of the FDA's regulatory and inspectional oversight of APIs. The audit took place from May 13 - 20, 2013.
The European Commssion published the implementing decision on the Webpage.
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?


